Early Stage Graves’ Disease is Uniformly Accompanied by Orbital Immune Activity even in Patients who Fail to Develop Orbithopathy during Follow-up

Abstract

Purpose Graves’ orbitopathy (GO) is a complication of Graves’ disease (GD), the development of which cannot be predicted at the time of diagnosis of GD. Our aims were (i) to test if orbital ^99mTc-labelled diethylenetriamine pentaacetic acid single-photon emission computer tomography (DTPA SPECT) can predict development of GO later during the course of the disease and (ii) to study whether orbital immune activity can be detected in GD patients who do not develop GO during follow-up.

Methods Fifty-four orbits of 27 patients with newly diagnosed GD were entered into the case-control study. Individuals showing signs of GO at enrolment were excluded. During the two-year follow-up, eye signs were recorded every 3 months. Orbital DTPA uptakes on SPECT images were measured when entering the study and at the end of the follow-up period, or when clinical signs of GO developed, whichever occurred first.

Results During the follow-up, 6 patients (22%) were diagnosed with GO. There was no significant difference between the initial DTPA uptakes of the patients with or without later developing GO (10.45±1.72 MBq/cm³ vs. 9.18±1.18 MBq/cm³ respectively). However, the DTPA uptakes of both GD groups (ie. with and without GO) were higher than that of the control group (7.45±1.36 MBq/cm³, p<0.05).

Conclusions We have shown that GD is accompanied by moderate orbital immune activity in GD patients without GO, irrespective of later development of GO. Why this orbital autoimmunity remains subclinical in the majority of the cases, and progresses into clinically detectable GO in others, remains unclear.

Key words

Thyroid - Graves’ disease - Graves’ orbithopathy - SPECT - Hyperthyroidism

• References

• 1 Bahn RS. Pathophysiology of Graves’ ophthalmopathy: The cycle of disease. J Clin Endocrinol Metab 2003; 88: 1939-1946
• 2 Bartalena L. The Dilemma of how to manage Graves' hyperthyroidism in patients with associated orbitopathy. J Clin Endocrinol Metab 2011; 96: 592-599
• 3 Marcocci C, Bartalena L, Bogazzi F. et al. Studies on the occurrence of ophthalmopathy in Graves' disease. Acta Endocrinol (Copenh) 1989; 120: 473-478
• 4 Bartalena L, Tanda ML. Graves’ Ophthalmopathy. N Engl J Med 2009; 360: 994-1001
• 5 Bartalena L, Baldeschi L, Dickinson A. et al. European Group on Graves' Orbitopathy (EUGOGO). Consensus statement of the European Group on Graves’ Orbitopathy (EUGOGO) on management of GO. Eur J Endocrinol 2008; 158: 273-285
• 6 Bartalena L, Baldeschi L, Boboridis K. et al. The 2016 European Thyroid Association/European Group on Graves’ Orbitopathy guidelines for the management of Graves’ Orbitopathy. Eur Thyroid J 2016; 5: 9-26
• 7 Bartalena L, Pinchera A, Marcocci C. Management of Graves’ ophthalmopathy: reality and perspectives. Endocr Rev 2000; 21: 168-199
• 8 Mourits MP, Koornneef L, Wiersinga WM. et al. Critical criteria for the assessment of disease activity in Gravesʼ ophthalmopathy: a novel approach. Br J Ophthalmol. 1989; 73: 639-644
• 9 Bartley GB, Gorman CA. Diagnostic criteria for Graves’ ophthalmopathy. Am J Ophthalmol 1995; 119: 792-795
• 10 Galuska L, Leovey A, Szucs-Farkas Z. et al. SPECT using ^99mTc-DTPA for the assessment of disease activity in Graves’ ophthalmopathy: A comparison with the results from MRI. Nucl Med Commun 2002; 23: 1211-1216
• 11 Galuska L, Varga J, Szucs Farkas Z. et al. Active retrobulbar inflammation in Graves’ ophthalmopathy visualized by Tc- ^99m DTPA SPECT. Clin Nucl Med 2003; 515-516
• 12 Galuska L, Leovey A, Szucs-Farkas Z. et al. Imaging of disease activity in Graves’ orbitopathy with different methods: Comparison of ^99mTc-DTPA and ^99mTc-depreotide single photon emission tomography, magnetic resonance imaging and clinical activity scores. Nucl Med Commun 2005; 26: 407-414
• 13 Ujhelyi B, Erdei A, Galuska L. et al. Retrobulbar ^99mTc-Diethylenetriamine-Pentaacetic-Acid uptake may predict the effectiveness of immunosuppressive therapy in Graves’ ophthalmopathy. Thyroid 2009; 19: 375-380
• 14 Ujhelyi B, Gogolak P, Erdei A. et al. Graves’ orbithopathy results in profound changes in tear composition: A study of plasminogen activator inhibitor-1 and seven cytokins. Thyroid 2012; 22: 407-414
• 15 Burch HB, Wartofsky L. Graves’ ophthalmopathy: current concepts regarding pathogenesis and management. Endocr Rev 1993; 14: 747-793
• 16 Marcocci C, Bartalena L, Bogazzi F. et al. Studies on the occurence of ophthalmopathy in Graves’ disease. Acta Endocrinol 1989; 120: 473-478
• 17 Weetman AP, Cohen S, Gatter KC. et al. Immunohistochemical analysis of the retrobulbar tissues in Graves’ ophthalmopathy. Clin Exp Immunol 1989; 75: 222-227
• 18 Heufelder AE, Bahn RS. Detection and localization of cytokine immunoreactivity in retro-ocular connective tissue in Graves’ ophthalmopathy. Eur J Clin Invest 1993; 23: 10-17
• 19 Kumar S, Bahn RS. Relative overexpression of macrophage-derived cytokines in orbital adipose tissue from patients with Graves’ ophthalmopathy. J Clin Endocrinol Metab 2003; 88: 4246-4250
• 20 Tallstedt L, Lundell G, Tørring O. et al. Occurrence of ophthalmopathy after treatment for Graves’ hyperthyroidism. N Engl J Med 1992; 326: 1733-1738
• 21 Bartalena L, Marcocci C, Bogazzi F. et al. Relation between therapy for hyperthyroidism and the course of Graves’ ophthalmopathy. N Engl J Med 1988; 338: 73-78
• 22 Träisk F, Tallstedt L, Abraham-Nordling M. et al. Thyroid-associated ophthalmopathy after treatment for Graves’ hyperthyroidism with antithyroid drugs or iodine-131. J Clin Endocrinol Metab 2009; 94: 3700 -3707
• 23 Villadolid MC, Yokoyama N, Nishikawa T. et al. Untreated Gravesʼ disease patients without clinical ophthalmopathy demonstrate a high frequency of extraocular muscle (EOM) enlargement by magnetic resonance. J Clin Endocrinol Metab 1995; 80: 2830-2833
• 24 Kahaly G, Görges R, Diaz M. et al. Indium-111-pentetreotide in Gravesʼ disease. J Nucl. Med. 1998; 39: 533-536